News &amp; Updates

A once-weekly oral antiretroviral therapy (ART) regimen combining the nucleoside reverse transcriptase translocation inhibitor (NRTTI) islatravir with the non-nucleoside reverse transcriptase inhibitor (NNRTI) ulonivirine helps maintain viral suppression in adults living with HIV-1, according to a phase IIb study.

Novel once-weekly oral ART regimen scores high for viral suppression maintenance

Inflammatory diet ups risk of constipation

Individuals with a high inflammatory diet are at increased risk of constipation, suggests a study. Moreover, gender and physical activity may influence such relationship.

Inflammatory diet ups risk of constipation

21 Aug 2025

Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women

In postmenopausal women with overweight or obesity, the use of tirzepatide alongside menopause hormone therapy appears to yield better weight loss outcomes than treating with tirzepatide alone, findings from a real-world analysis have shown.

Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women

21 Aug 2025

Anxiety in high-risk pregnancy ups risk of arterial stiffness, pre-eclampsia

Women with high-risk pregnancies who have anxiety are at increased risk of arterial stiffness and, potentially, pre-eclampsia, as suggested in a study.

Anxiety in high-risk pregnancy ups risk of arterial stiffness, pre-eclampsia

Gender-neutral HPV vaccination – an important emerging need

The increasing incidence of human papillomavirus (HPV)–related diseases in males over recent years is turning the spotlight on gender-neutral vaccination (GNV) to prevent HPV-related diseases and cancers in both sexes. Professor Hung-Hsueh Chou from the National Tsing Hua University, Hsinchu, Taiwan, and Dr Mike Yat-Wah Kwan, President of the Asian Society for Pediatric Infectious Diseases (ASPID), and other experts in Hong Kong shared insights on the need for gender-neutral HPV vaccination, as well as possible ways to overcome vaccination barriers and bridge the gender gap.

Gender-neutral HPV vaccination – an important emerging need

Preventive fremanezumab sustains reductions in migraine days up to 2 years in real world

In the final analysis of the real-world PEARL study presented at EAN 2025, fremanezumab as a preventive treatment for chronic or episodic migraine halves the number of monthly migraine days or more from 3 months onwards through 24 months

Preventive fremanezumab sustains reductions in migraine days up to 2 years in real world

Novel selective OX2R antagonist works well for people with insomnia

20 Aug 2025 by

The novel selective orexin-2 receptor (OX2R) antagonist seltorexant helped promote sleep in people with insomnia, with the efficacy maintained over a 2-week treatment period, according to a phase 2b study.

Novel selective OX2R antagonist works well for people with insomnia

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

The use of fenestrated stents results in longer patency, fewer complications, and improved biomechanical performance than conventional silicone stents, without compromising the structural integrity of the stent, according to a study.

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

20 Aug 2025 by

Patients with postbariatric hypoglycaemia (PBH) may benefit from using mizagliflozin, which contributes to significant reductions in hypoglycaemic events, reports a study presented at ENDO 2025.

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia